Obstructive Lung Disease Models: What Is Valid?

REFERENCES

• Mannino D M, Homa D M, Akinbami L J, Ford E S, Redd S C. Chronic obstructive pulmonary disease surveillance—United States—197–2000. Morbid Mortal Weekly Rept 2002; 51: 1–16
   PubMed Web of Science ®Google Scholar
• Mannino D M, Homa D M, Akinbami L J, Moorman J E, Gwynn C, Redd S C. Surveillance for Asthma—United States, 1980–1999. Morbid Mortal Weekly Report 2002; 51: 1–13
   Google Scholar
• U.S. Centers for Disease Control and Prevention. Asthma: General Information. US Centers for Disease Control and Prevention, Atlanta 4-6-2007, Report
   Google Scholar
• U.S. Department of Health and Human Services. Facts about Chronic Obstructive Pulmonary Disease (COPD). Atlanta, US Centers for Disease Control and Prevention. 4-6-2007, Report
   Google Scholar
• U.S. Department of Health and Human Services. Healthy People 2010: Understanding and Improving Health, 2nd Ed. US Government Printing Office Report, Washington, DC, 017-001-001-00-550-9. 11-1-2000
   Google Scholar
• Philips Z, Ginnelly L, Sculpher M, Claxton K, Golder S, Riemsma R, et al. Review of guidelines for good practice in decision-analytic modelling in health technology assessment. Health Technol Assess 2004; 8: iii–xi1
   PubMed Web of Science ®Google Scholar
• Weinstein M C, Toy E L, Sandberg E A, Neumann P J, Evans J S, Kuntz K M, et al. Modeling for health care and other policy decisions: uses, roles, and validity. Value Health. 2001; 4: 348–361
   PubMedGoogle Scholar
• Weinstein M C, O'Brien B, Hornberger J, Jackson J, Johannesson M, McCabe C, et al. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices—Modeling Studies. Value Health 2003; 6: 9–17
   PubMed Web of Science ®Google Scholar
• Buist A S, Vollmer W M, Sullivan S D, Weiss K B, Lee T A, Menezes A M, et al. The Burden of Obstructive Lung Disease Initiative (BOLD): rationale and design. COPD J 2005; 2: 277–283
   PubMedGoogle Scholar
• Lee T A, Rutten-van Molken M P. Economic modeling in chronic obstructive pulmonary disease. Proceedings of the American Thoracic Society 2006; 3: 630–634
   PubMedGoogle Scholar
• Eddy D M. Technology Assessment: The Role of Mathematical Modeling. Assessing Medical Technologies, F Mosteller. National Academy Press, Washington, DC 1985; 144–160
   Google Scholar
• Combescure C, Chanez P, Saint-Pierre P, Daures J P, Proudhon H, Godard P. Assessment of variations in control of asthma over time. Eur RespirJ 2003; 22: 298–304
   PubMed Web of Science ®Google Scholar
• Fuhlbrigge A L, Bae S J, Weiss S T, Kuntz K M, Paltiel A D. Cost-effectiveness of inhaled steroids in asthma: impact of effect on bone mineral density. J Allergy Clin Immunol 2006; 117: 359–366
   PubMed Web of Science ®Google Scholar
• Paltiel A D, Fuhlbrigge A L, Kitch B T, Liljas B, Weiss S T, Neumann P J, et al. Cost-effectiveness of inhaled corticosteroids in adults with mild-to-moderate asthma: results from the asthma policy model. J Allergy Clin Immunol 2001; 108: 39–46
   PubMed Web of Science ®Google Scholar
• Price M J, Briggs A H. Development of an economic model to assess the cost effectiveness of asthma management strategies. Pharmacoeconomics 2002; 20: 183–194
   PubMed Web of Science ®Google Scholar
• Saint-Pierre P, Combescure C, Daures J P, Godard P. The analysis of asthma control under a Markov assumption with use of covariates. Stat Med 2003; 22: 3755–3770
   PubMed Web of Science ®Google Scholar
• Wild D M, Redlich C A, Paltiel A D. Surveillance for isocyanate asthma: a model based cost effectiveness analysis. Occup Environ Med 2005; 62: 743–749
   PubMed Web of Science ®Google Scholar
• Borg S, Ericsson A, Wedzicha J, Gulsvik A, Lundback B, Donaldson G C, et al. A computer simulation model of the natural history and economic impact of chronic obstructive pulmonary disease. Value Health 2004; 7: 153–67
   PubMed Web of Science ®Google Scholar
• Feenstra T L, van Genugten M L, Hoogenveen R T, Wouters E F, Rutten-van Molken M P. The impact of aging and smoking on the future burden of chronic obstructive pulmonary disease: a model analysis in the Netherlands. Am J Respir Crit Care Med 2001; 164: 590–596
   PubMed Web of Science ®Google Scholar
• Hoogendoorn M, Rutten-van Molken M P, Hoogenveen R T, van Genugten M L, Buist A S, Wouters E F, et al. A dynamic population model of disease progression in COPD. Eur RespirJ 2005; 26: 223–233
   PubMed Web of Science ®Google Scholar
• Johansson P M, Tillgren P E, Guldbrandsson K A, Lindholm L A. A model for cost-effectiveness analyses of smoking cessation interventions applied to a Quit-and-Win contest for mothers of small children. Scand J Public Health 2005; 33: 343–352
   PubMed Web of Science ®Google Scholar
• Oostenbrink J B, Rutten-van Molken M P, Monz B U, Fitz Gerald J M. Probabilistic Markov model to assess the cost-effectiveness of bronchodilator therapy in COPD patients in different countries. Value Health 2005; 8: 32–46
   PubMed Web of Science ®Google Scholar
• Sin D D, Golmohammadi K, Jacobs P. Cost-effectiveness of inhaled corticosteroids for chronic obstructive pulmonary disease according to disease severity. Am J Med 2004; 116: 325–331
   PubMed Web of Science ®Google Scholar
• Spencer M, Briggs A H, Grossman R F, Rance L. Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease. Pharmacoeconomics 2005; 23: 619–637
   PubMed Web of Science ®Google Scholar
• Gold M R, Siegel J E, Russell L B, Weinstein M C. Cost-Effectiveness in Health and Medicine. Oxford University Press, New York 1996
   Google Scholar